Surveillance of SARS-CoV-2 lineage B.1.1.7 in Slovakia using a novel, multiplexed RT-qPCR assay

Posted: 2021-10-15 19:00:00
The emergence of a novel SARS-CoV-2 B.1.1.7 variant sparked global alarm due to increased transmissibility, mortality, and uncertainty about vaccine efficacy, thus accelerating efforts to detect and track the variant. Current approaches to detect B.1.1.7 include sequencing and RT-qPCR tests containing a target assay that fails or results in reduced sensitivity towards the B.1.1.7 variant. Since many countries lack genomic surveillance programs and failed assays detect unrelated variants containing similar mutations as B.1.1.7, we used allele-specific PCR, and judicious placement of LNA-modified nucleotides to develop an RT-qPCR test that accurately and rapidly differentiates B.1.1.7 from other SARS-CoV-2 variants. We validated the test on 106 clinical samples with lineage status confirmed by sequencing and conducted a country-wide surveillance study of B.1.1.7 prevalence in Slovakia. Our multiplexed RT-qPCR test showed 97% clinical sensitivity and retesting 6,886 SARS-CoV-2 positive samples obtained during three campaigns performed within one month, revealed pervasive spread of B.1.1.7 with an average prevalence of 82%. Labs can easily implement this test to rapidly scale B.1.1.7 surveillance efforts and it is particularly useful in countries with high prevalence of variants possessing only the ΔH69/ΔV70 deletion because current strategies using target failure assays incorrectly identify these as putative B.1.1.7 variants.

参考サイト PubMed: covid-19


9月 23, 2020 バイオアソシエイツ


2019年後半に中国の武漢市で初めて出現したSARS-CoV-2ウイルスは、世界中で病気と死を引き起こしている。 既に承認された医薬品の転用を含め、 COVID-19 を治療するための複数のソリューションが検討されてきたが、この研究は非常に有望な治療オプションを指摘している。シカゴ大学のプリツカー分子工学大学院(PME)の研究チームは、最先端のコンピューターシミュレーションを使用して、この世界的なパンデミックの解決策を迅速に追跡できる既存の薬物を特定した。 彼らの発見は、2020年8月14日にScience…

ゲスト 855人 と メンバー 4人 がオンラインです